Innegligible musculoskeletal disorders caused by zoledronic acid in adjuvant breast cancer treatment: a meta-analysis

BACKGROUND: Zoledronic acid (ZOL) is widely used for preventing bone loss in early breast cancer patients. However, the adverse effects caused by ZOL itself should not be neglected. Musculoskeletal disorders were common after ZOL administration and distressing to the patients. Up to now, no precise...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Wen-Bin, Zhang, Peng-Ling, Liu, Xiao-An, Yang, Tao, He, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3159097/
https://www.ncbi.nlm.nih.gov/pubmed/21816036
http://dx.doi.org/10.1186/1756-9966-30-72

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3159097/
https://www.ncbi.nlm.nih.gov/pubmed/21816036
http://dx.doi.org/10.1186/1756-9966-30-72

Ejemplares similares